Teijin Limited revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company expected revenue of JPY 860,000 million compared to previous guidance of JPY 860,000 million a year ago, Operating loss in range of JPY 75,000 million - JPY 85,000 million compared to previous guidance of Operating income of JPY 5,000 million. Loss attributable to owners of parent range of JPY 85,000 million - JPY 95,000 million as compared to previous loss guidance of JPY 10,000 million.

Basic loss per share of JPY JPY 440.76 - JPY 492.62 compared to previous loss guidance of JPY 51.85. Reasons for revision of earnings forecasts: As announced in the Notice of Change in Equity Method Affiliates (Share Transfer) dated August 29, 2025, Teijin Limited resolved to transfer its shares in DuPont Teijin Advanced Papers (Japan) Limited and DuPont Teijin Advanced Papers (Asia) Limited. However, Completion of the share transfer is expected to be delayed into the fiscal year ending March 2027 (completion is scheduled for April 1, 2026).

In addition, the Company is considering selectively narrowing the portfolio of its pharmaceutical business, aside from the rare/intractable disease areas that it focuses on, to fundamentally improve its profitability. As part of this measure, Teijin Pharma Limited, a consolidated subsidiary of the Company, reevaluated the recoverable amount of the sales rights for diabetes treatments, and concluded that there was a high likelihood of an impairment loss being recorded. Furthermore, in light of the above, Teijin Limited and Teijin Pharma Limited reassessed the recoverability of deferred tax assets, concluding that the likelihood of needing to write down a part of the deferred tax assets has increased.